Hansel Laboratory Department of Pathology

Hansel Lab Publications

Click here to search for other Hansel Lab publications

  1. Argininosuccinate Synthetase-1 (ASS1) Loss in High-Grade Neuroendocrine Carcinomas of the Urinary Bladder: Implications for Targeted Therapy with ADI-PEG 20. Gupta S, Sahu D, Bomalaski JS, Frank I, Boorjian SA, Thapa P, Cheville JC, Hansel DE. Endocr Pathol, 2018 Feb 16 doi. 10. 1007/s12022-018-9516-9 [Epub ahead of print].
  2. Analysis of T1 Bladder Cancer on Biopsy and Transurethral Resection Specimens: Comparison and Ranking of T1 Quantification Approaches to Predict Progression to Muscularis Propria Invasion. Leivo MZ, Sahoo D, Hamilton, Mirsadraei L, Shabaik A, Parsons JK, Kader AK, Derweesh, Kane C, Hansel DE. Am J Surg Pathol 2018 2018 Jan; 42(1): e1-e10, doi: 10.1097/PAS.
  3. Serous Carcinoma Mimicking Primary Urothelial Carcinoma on Clinical Evaluation and Pathology: A Potential Diagnostic Pitfall. Mirsadraei L, Hodkoff A, Jones K, Shabaik A, Kader AK, Saenz CC, Montironi R, Tacha DE, Fadare O, Hansel DE. Arch Pathol Lab Med 2018 Feb; 142(2): 168-177.
  4. Differential mTOR Pathway Profiles in Bladder Cancer Cell Line Subtypes to Predict Sensitivity to mTOR Inhibition. Hau AM, Nakasaki M, Nakashima K, Krish G, Hansel DE. Urol Oncol 2017 Oct; 35(10): 593-599.
  5. Argininosuccinate Synthetase 1 Loss in Invasive Bladder Cancer Regulates Survival through General Control Nonderepressible 2 Kinase-Mediated Eukaryotic Initiation Factor 2α Activity and Is Targetable by Pegylate Arginine Deiminase. Sahu D, Gupta S, Hau AM, Nakashima K, Leivo MZ, Searles SC, Elson P, Bomalaski JS, Casteel DE, Boss GR, Hansel DE. Am J Pathol 2016 Dec. 9 pii: S0002-9440(16)30407-2.
  6. mTORC2 Activiation is Regulated by the Urokinase Receptor (uPAR) in Bladder Cancer. Hau Am, Leivo MZ, Gilder AS, HU JJ, Gonias SL, Hansel DE. Cell Signal 2017 Jan; 29:96-106.
  7. The Emerging Molecular Landscape of Urothelial Carcinoma. Solomon JP, Hansel DE. Surg Pathol Clin 2016 Sep; 9(3): 391-404.
  8. Transforming Growth Factor-β is an Upstream Regulator of Mammalian Target of Rapamycin Complex 2-Dependent Bladder Cancer Cell Migration and Invasion. Gupta S, Hau AM, Al-Ahmadie HA, Harwalkar J, Shoskes AC, Elson P, Beach JR, Hussey GS, Schiemann WP, Egelhoff TT, Howe PH, Hansel DE. Am J Path 2016 May; 186(5):1351-60.
  9. Mammalian Target of Rapamycin Complex 2 (mTOR) is Critical Determinant of Bladder Cancer Invasion. PLoS One 2013 Nov 27;8(11):e81081.
  10. Mammalian Target of Rapamycin (mTOR) Regulates Cellular Proliferation and Tumor Growth in Urothelial Carcinoma. Hansel DE, Platt E, Orloff M, Harwalker J, Sethu S, Hicks JL, De Marzo A, Steinle RE, Hsi ED, Theodorescu D, Ching CB, Eng C. Am J Pathol. 2010 Jun;176(6):3062-72.

Page 'Breadcrumb' Navigation:

External Resources: